Figure 5 from Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma by Zelei Yang (18491142)

“…The individual points for each cell line in the individual graph for each treatment represent the average of three experiments, and error bars represent standard error of the mean. An ordinary one-way ANOVA with Šídák’s multiple comparisons test was performed to assess the significance of the difference between either the 4 hour or the 24 hour timepoint and the 45 minute timepoint for each cell line within each treatment. …”

Image 1_Sepsis in Internal Medicine: blood culture-based subtypes, hospital outcomes, and predictive biomarkers.tiff by Gaetano Zizzo (15853004)

“…Median length of stay (LOS) was 14 days, and mean ward-to-intensive care unit (ICU) transfer and in-hospital mortality rates were 11 and 26%, respectively; significant differences were observed over the years, with LOS peaks preceding mortality peaks by 1 year. …”

Image 2_Sepsis in Internal Medicine: blood culture-based subtypes, hospital outcomes, and predictive biomarkers.tiff by Gaetano Zizzo (15853004)

“…Median length of stay (LOS) was 14 days, and mean ward-to-intensive care unit (ICU) transfer and in-hospital mortality rates were 11 and 26%, respectively; significant differences were observed over the years, with LOS peaks preceding mortality peaks by 1 year. …”

Data Sheet 1_Effects of low-temperature stress during rice heading stage on carbon and nitrogen allocation in paddy eco-system of northeastern China.docx by Tao Sun (91038)

“…</p>Results and Discussion<p>Low-temperature stress significantly reduced rice grain yield of JN809 (sensitive to low-temperature stress) and J88 (tolerant to low-temperature stress) varieties by 27.6% and 21.4%, respectively, This stress tendency increased C and N accumulation in rice stems and leaves, while concurrently decreasing C and N accumulation in panicles. …”

Supplementary Material for: Off-label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-analysis by Feng L. (5056958)

“…Conclusion: MMF administration in IgAN indicates promising in decreasing the occurrence of MAKDE, reducing proteinuria level, and lessening the probability of doubling blood creatinine, but also comes with the risk of infection. …”

The global disability-adjusted life years (DALYs) for asthma attributable to nitrogen dioxide pollution from 1990 to 2021 and predicted the trends from 2022 to 2050 by Yaping Feng (427666)

“…Additionally, it is still quite significant for children under the age of 15 and in some underdeveloped regions.…”

Supplemental Material For Coronary Microvascular Remodeling in Pressure-Overload RV by Ilham Essafri (21688937)

“…Sex-based differences were observed primarily in SHAM mice, with no distinct, sex-specific response to PAB, except for hemodynamic resistance, which was higher in healthy males and declined only in male PAB mice to levels observed in SHAM females. Notably, resistance was significantly higher in male SHAM mice compared to females at baseline, and decreased in males but not in females post-PAB. …”

Data Sheet 1_Huoxue-Jiangtang decoction ameliorates type 2 diabetes in high-fat diet and streptozotocin-induced rats.pdf by Maosheng Lee (13041531)

“…The Western blot results indicated that HXJT reversed the downregulation of AKT and PI3K and markedly increased glucose transporter type 4 (GLUT4) in skeletal muscles. Moreover, the levels of glycogen synthetase (GS), hexokinase, superoxide dismutase (SOD), glycogen, and muscle glycogen in the HXJT group significantly increased relative to those in untreated T2DM group, while TNF-α levels decreased observably. …”

eIF3d1 phosphorylation but not cap-binding is required for CySC self-renewal. by Ruoxu Wang (9312306)

“…Phospho-dead eIF3d1 expression results in a significant decrease in CySC numbers (<i>N</i> ≥ 18 testes, * <i>P</i> < 0.05, ns <i>P</i> = 0.1150 (eIF3d1^WT) or <i>P</i> > 0.9999 (eIF3d1^DD), Kruskal-Wallis test). …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”